Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
AVI BioPharma, Inc.
Positive results reported with Neugene antisense drugs
July 6th, 2005
AVI BioPharma, Inc., (AVII), announced presentation of positive results from two preclinical studies at the 87th Annual Meeting of the Endocrine Society held in San Diego June 4-7, 2005. The presentations discussed application of Neugene antisense drugs for treating prostate cancer and overcoming chemotherapy resistance in ovarian cancer. "These study results add to our existing knowledge of the role of Neugenes antisense drugs in cancer," said Patrick L. Iversen, PhD, senior vice president of research and development at AVI. "The prostate cancer study, which was sponsored in part by the National Cancer Institute, demonstrates our ability to...
Source: Biotech Week (2005-07-06)
|
